Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.56 |
| ▸ | KIF11 | P52732 | 2/20 | 0.50 |
| ▸ | PARG | Q86W56 | 2/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 3/20 | 0.40 |
| ▸ | CA9 | Q16790 | 3/20 | 0.40 |
| ▸ | FEN1 | P39748 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.38 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.38 |
| ▸ | DNASE1 | P24855 | 1/20 | 0.38 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.38 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3374821 | 0.87 | ADORA3 (0.56) | ADORA3ADORA2BADORA2AADORA1KIF11 | |
| SCHEMBL15651338 | 0.80 | LMNA (0.53) | ADORA3ADORA2BADORA2AADORA1KIF11 | |
| SCHEMBL8215674 | 0.78 | ADORA3 (0.61) | ADORA3ADORA2BADORA2AADORA1PARG | |
| SCHEMBL9919008 | 0.77 | ADORA3 (0.64) | ADORA3ADORA2BADORA2AADORA1PARG | |
| SCHEMBL5355203 | 0.77 | CA12 (0.66) | ADORA3ADORA2BADORA2AADORA1PARG | |
| SCHEMBL9923029 | 0.77 | ADORA3 (0.59) | ADORA3ADORA2BADORA2AADORA1PARG | |
| SCHEMBL9919007 | 0.77 | CA9 (0.66) | ADORA3ADORA2BADORA2AADORA1PARG | |
| SCHEMBL9919006 | 0.77 | FEN1 (0.66) | ADORA3ADORA2BADORA2AADORA1PARG | |
| SCHEMBL5712368 | 0.77 | ADORA3 (0.59) | ADORA3ADORA2BADORA2AADORA1PARG | |
| SCHEMBL31709875 | 0.77 | ADORA3 (0.64) | ADORA3ADORA2BADORA2AADORA1PARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3929207-A1 | INHIBITION OF PULMONARY FIBROSIS WITH NUTLIN-3A AND PEPTIDES | Board of Regents, The University of Texas System (US) | 2021-12-29 | — | — | EP | claimed |
| US-20180086791-A1 | INHIBITION OF PULMONARY FIBROSIS WITH NUTLIN-3A AND PEPTIDES | UNIV TEXAS (US) | 2018-03-29 | — | — | US | claimed |
| EP-3929207-B1 | PEPTIDE FTTFTVT FOR USE IN TREATING FIBROSIS | UNIV TEXAS (US) | 2024-07-17 | — | — | EP | disclosed |
| US-20240067713-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CHRONIC LUNG DISEASES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240059736-A1 | INHIBITION OF PULMONARY FIBROSIS WITH NUTLIN-3A AND PEPTIDES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-02-22 | — | — | US | disclosed |
| US-11905336-B2 | Modified peptide fragments of CAV-1 protein and the use thereof in the treatment of fibrosis | LUNG THERAPEUTICS, INC. (US) | 2024-02-20 | — | — | US | disclosed |
| US-20240018186-A1 | MODIFIED PEPTIDE FRAGMENTS OF CAV-1 PROTEIN AND THE USE THEREOF IN THE TREATMENT OF FIBROSIS | LUNG THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | US | disclosed |
| WO-2024015857-A2 | MODIFIED CAVEOLIN-1 PEPTIDE FORMULATIONS AND METHODS OF MANUFACTURING AND USE THEREOF | LUNG THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| US-11787838-B2 | Modified peptide fragments of CAV-1 protein and the use thereof in the treatment of fibrosis | LUNG THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11780879-B2 | Inhibition of pulmonary fibrosis with nutlin-3A and peptides | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-10-10 | — | — | US | disclosed |
| WO-2023154916-A2 | COMPOSITIONS AND METHODS FOR TREATING INFECTIOUS DISEASES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2001098343-A9 | CONSERVED DIAPHANOUS-RELATED FORMIN AUTOREGULATORY DOMAIN (DAD) | ANDEL INST VAN (US) | 2003-03-06 | — | — | WO | disclosed |
| WO-2003012395-A2 | EARLY DETECTION OF MYCOBACTERIAL DISEASE USING PEPTIDES | NEW YORK UNIVERSITY (US) | 2003-02-13 | — | — | WO | disclosed |
| US-20030027768-A1 | Anti-invasive and anti-angiogenic compositions | MAZAR ANDREW P (US) | 2003-02-06 | — | — | US | disclosed |
| WO-2002069885-A2 | ANTI-INVASIVE AND ANTI-ANGIOGENIC COMPOSITIONS AND METHODS FOR TREATING BRAIN TUMORS AND OTHER DISEASES | ANGSTROM PHARMACEUTICALS, INC. (US) | 2002-09-12 | — | — | WO | disclosed |
| WO-2002014369-A2 | HUMAN KININOGEN D5 DOMAIN POLYPEPTIDES AND THEIR USE | ATTENUON, LLC (US) | 2002-02-21 | — | — | WO | disclosed |
| WO-2001098343-A2 | CONSERVED DIAPHANOUS-RELATED FORMIN AUTOREGULATORY DOMAIN (DAD) | VAN ANDEL INSTITUTE (US) | 2001-12-27 | — | — | WO | disclosed |
| US-5994309-A | OCTAPEPTIDE; ANTITUMOR AGENT | ANGSTROM PHARMACEUTICALS, INC. (US) | 1999-11-30 | — | — | US | disclosed |
| EP-0950096-A1 | ANTI-INVASIVE AND ANTI-ANGIOGENIC UROKINASE FRAGMENTS AND THEIR USE | Angstrom Pharmaceuticals, inc. (US) | 1999-10-20 | — | — | EP | disclosed |
| WO-1999005263-A1 | ANTI-INVASIVE AND ANTI-ANGIOGENIC UROKINASE FRAGMENTS AND THEIR USE | ANGSTROM PHARMACEUTICALS, INC. (US) | 1999-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086791-A1 | INHIBITION OF PULMONARY FIBROSIS WITH NUTLIN-3A AND PEPTIDES | IGFBP4, FN1, MDM2 | ADORA3 3688/4885ADORA2B 4070/4885ADORA2A 3853/4885 |
| US-20240059736-A1 | INHIBITION OF PULMONARY FIBROSIS WITH NUTLIN-3A AND PEPTIDES | IGFBP4, FN1, MDM2 | ADORA3 3688/4885ADORA2B 4070/4885ADORA2A 3853/4885 |
| US-11780879-B2 | Inhibition of pulmonary fibrosis with nutlin-3A and peptides | IGFBP4, FN1, MDM2 | ADORA3 3688/4885ADORA2B 4070/4885ADORA2A 3853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.